A Double‐Blind, Randomized, Controlled Trial of Lovastatin in Early‐Stage Parkinson's Disease
Authors:
- 15 January 2021
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 36 (5) , 1229-1237
Abstract
Background: Recent evidence indicates that lipophilic statins have a neuroprotective benefit in animal models of Parkinson's disease (PD). The objective of this study was to evaluate whether lovastatin has the potential to slow motor symptom progression in patients with early‐stage PD.Methods: This double‐blind, randomized, placebo‐controlled trial enrolled 77 patients with early‐stage PD between May 23, 2017, and July 12, 2018, with follow‐up ending September 1, 2019. Lovastatin 80 mg/day or placebo with 1:1 randomization was administered for 48 weeks. Mean change in the parts I–III scores of the Movement Disorder Society–Unified Parkinson's Disease Rating Scale (MDS‐UPDRS), changes in the striatal dopamine uptake ratio measured by 18F‐dopa PET scan, and changes in PD medications between baseline and the week 48 visit were measured.Results: Of the 77 randomized patients, 70 (90.9%) completed the study. There was a slightly beneficial trend of the MDS‐UPDRS motor score in the lovastatin group (−3.18 ± 5.50) compared with the placebo group (−0.50 ± 6.11); P = 0.14 adjusted for age, sex, disease duration, and baseline LEDD. Mean percentage change in the striatal 18F‐dopa uptake ratio deteriorated less in the lovastatin group than in the placebo group on the dominant side of caudate (1.2% ± 7.3% vs −7.1% ± 8.2%, P < 0.01) and putamen (2.3% ± 7.1% vs −6.4% ± 8.1%, P < 0.01). We found no between‐group differences in the change in part I or part II MDS‐UPDRS scores. Lovastatin was generally well tolerated.Conclusions: Lovastatin treatment in patients with early‐stage PD was associated with a trend of less motor symptom worsening and was well tolerated. A future larger long‐term follow‐up study is needed to confirm our findings. © 2021 International Parkinson and Movement Disorder SocietyKeywords
Funding Information
- Ministry of Health and Welfare (MOHW107‐TDU‐B‐211‐123002, MOHW108‐TDU‐B‐211‐133002)
- National Taiwan University Hospital (PCB‐106)
This publication has 30 references indexed in Scilit:
- Prospective Study of Statin Use and Risk of Parkinson DiseaseArchives of Neurology, 2012
- Statin Myopathy: A Lipid Clinic Experience on the Tolerability of Statin RechallengeCardiovascular Therapeutics, 2011
- Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trialThe Lancet, 2010
- Statin use and Parkinson's disease in DenmarkMovement Disorders, 2010
- Statins and neuroprotectionAnnals of the New York Academy of Sciences, 2010
- Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch databaseBMJ, 2010
- Lovastatin ameliorates α-synuclein accumulation and oxidation in transgenic mouse models of α-synucleinopathiesExperimental Neurology, 2010
- Statin use and the risk of Parkinson diseaseNeurology, 2008
- Statins reduce neuronal α‐synuclein aggregation in in vitro models of Parkinson’s diseaseJournal of Neurochemistry, 2008
- Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030Neurology, 2007